RATIONALE: Oral steroid is the only non-biologic immunomodulator approved by the FDA for treatment of atopic dermatitis (AD). However, no studies have examined the effects of a short course of prednisolone in patients with AD on physician and patient reported outcomes. METHODS: Sixteen patients with moderate-to-severe AD washed out of systemic medications for 30 days, and randomized (1:1) to placebo or prednisolone for 5 days at 0.75 mg/kg, 5 days at 0.5 mg/kg and 5 days at 0.25 mg/kg. Physician reported outcomes (EASI, SCORAD and IGA) and patient reported outcomes (POEM and DLQI) and were assessed. The percent change in scores was calculated and compared between treatment groups and patient and physician scores were also compared. RESULTS: Compared to placebo, prednisolone treatment significantly improved EASI, SCORAD, IGA, and POEM scores (p< _0.05) after 7 days of treatment, with no significant effect on DLQI (p50.26). The changes in scores at day 7 weakly but significantly correlated between EASI vs POEM (r50.48), EASI vs DLQI (r50.46), SCORAD vs POEM (r50.54) and SCORAD vs DLQI (r50.55), all p<0.05. Compared to placebo, no difference was observed compared to placebo at the lowest dose of prednisolone measured after 14 days of treatment. CONCLUSIONS: Prednisolone improved clinical responses in adults with moderate-to-severe AD in a dose-dependent manner, in this small, short time course study. There was a positive relationship between the improvements in physician and patient reported outcomes. These data indicate that the subjective experience of the patient is an important marker of drug efficacy.
404
The Effect of omalizumab in Mastocytosis Patients. Prospective double-blind, placebocontrolled multicentre study METHODS: The effect of omalizumab was investigated in 17 mastocytosis patients in a multicenter prospective double-blind placebo-controlled trial. 7 were randomised to the omalizumab group, 9 to placebo.The primary endpoint of the study was the change in the AFIRMM score after 6 months of treatment. Groups were age-balanced , whereas 66,6% in the omalizumab and 85.7% in placebo group were female. A variety of laboratory parameters were also analyzed. RESULTS: After 6 months the median AFIRMM score improved from 104.0 to 102.0 in the placebo and from 52.0 to 26.0 in the omalizumab group, respectively (p50.286). The amount of reduction was not significantly different (p50.941). Regarding the secondary endpoints showed a slight, but not significant improvement in the omalizumab group. Adverse events (AE) showed no significant difference between the groups. The expression of FceRI on basophils was lower in patients receiving omalizumab than in the placebo group. CONCLUSIONS: The conclusions that can be drawn from this study are limited due to the small study sample.However, omalizumab seems to improve mastocytosis symptoms in particular diarrhea, dizziness, flush, and anaphylactic reactions. Moreover the AFIRMM score and the secondary endpointsimproved.To our knowledge, this is the first doubleblind placebo controlled study for omalizumab in mastocytosis.
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Gamaglobulin infusion in patients with severe atopic dermatitis Federal University of Sao Paulo, Sao Paulo, Brazil. RATIONALE: Atopic dermatitis (AD) is a chronic, recurrent, inflammatory disease, characterized by intense itching and eczema. Severe patients may need immunosuppressive and immunobiological therapies to reach control. METHODS: Serie of 5 severe cases of AD using immunosuppressive drugs without improvement, which received intravenous immunoglobulin (IVIG) infusion. In the first month they received 2g/kg/month divided into 2 days, then 1g/kg/day each month. After 6 months infusion, clinical presentation Scoring Atopic Dermatitis (SCORAD) and patient's quality of life (CDLQI) were evaluated. RESULTS: Patients aged 11 to 16 years had a proportional improvement in quality of life and clinical presentation. Two patients presented partial response in clinical picture and 60% of patients improved significantly according to SCORAD, with values -from 59, 42, 37 before infusion to 22, 12, 19 after 6 months, respectively. This therapeutic procedure allowed to reduce and even to suspend oral corticosteroid and cyclosporine. One patient presented disseminated contagious molluscum after immunosuppression with methotrexate, and after IVIG, lesions regressed without recurrence. Only one patient did not continue with therapy because of aseptic meningitis after the first month of treatment and headache at following doses. IVIG side effects were observed in some cases but were not as prevalent as patient improvement. CONCLUSIONS: When analyzing the improvement in clinical presentation and quality of life, IVIG should be considerate an alternative therapeutic option for severe AD patients, because it could be able to reduce the severity and reclassify this patients as moderate and even mild it.
